The FDA approval of TNKase (tenecteplase) represents a historic step in the fight against acute ischemic stroke (AIS). Roche’s new drug is the first of its kind to be approved in nearly 30 years, providing fresh hope for stroke patients and transforming the acute ischemic stroke treatment landscape. What is Acute Ischemic Stroke? Acute ischemic… Read.